reason report
outlook set rais view pt
bottom line remain top mid-cap pick
continu consid one best margin expans stori
mid/large-cap med-tech acceler above-avg hsd revenue
ep growth potenti next year rev/
ep guid expect would think
set anoth year beat rais given believ
manta handili exceed assum headwind
relat coronaviru steril could well prove
conserv view worst case play unexpect
tuck-in acquisit hpc also posit surpris
addit revenue growth op margin right gate
deal increas confid upward bia potenti out-
year consensu estim given consist track record under-
promis over-deliv pt increas vs
assum price-to-earnings higher ep y/i
cc growth in-lin gm op margin miss lower tax
interest rate drive ep upsid modestli beat
consensu org cc sell day adjust revenue growth y/
compar street steril headwind
relat third-parti provid essenti off-set extra sell
within america cc outperform expect
signific urolift out-performance asia cc in-lin
emea cc driven distributor order time shift
led urolift intervent urolog cc beat
surgic oem roughli in-lin
vascular access cc intervent cc anesthesia
cc cc under-perform estim urolift
manta compris growth remain come
base busi would closer
steril impact turn gm
consensu consensu op mgn
miss lower interest expens tax rate help adj
ep beat our/consensu think
set rais recal guid
outset deliv report rang work
reflect cc inclus hpc
acquisit organ growth thu assum
headwind coronaviru linger steril headwind
price-to-earnings lt ep growth
medic suppli devic
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present note valuat base pf ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
thu true underli organ guid would closer
consensu revenue guid assumpt
growth hpc acquisit headwind
steril issu coronaviru headwind
primarili fx headwind pronounc
less sell day extra sell day addit day
management expect revenue total revenue reflect
urolift manta guidanc particular leav room upsid
view model revenue upper end cc revenue guidanc
urolift ul expect grow y/i reflect deceler
y/i growth believ conservat management
suggest reason think momentum slow
fact opposit happen given stepped-up spend behind
nation dtc pilot initi model think prove
upsid lever meanwhil manta outlook also strike us overli
conserv management expect ww revenue reach penetr
company-estim ww market oppti midpoint
revenue vs exclus ou revenue would
impli us manta revenue think compani least
us overal model cc organ growth cc
overal growth upper-end outlook rang
turn adj ep guidanc y/i rang
captur our/consensu estim upper
end includ cv/sterilization/fx headwind aggreg
amount headwind key assumpt adj gm
vs svbl/cn reflect y/i
expans adj op margin vs svbl
reflect y/i expans interest
headwind modest accret hpc acquisit
hpc acquisit posit addit oem divis
high perform conductor inc hpc
estim reflect ntm ev/sal hpc industry-lead
manufactur insul wire micro-diamet tube compon
medic devic acquisit enhanc oem busi
ad two highli complementari differenti platform includ
ultra-fin wire tubing/cathet therapeut applic
fast-grow market ep peripher manag pain
manag ultra-fin wire compon conduct electr
healthcar applic hpc above-compani averag revenue
growth profil low teen despit gm profil below-compani
average low op margin profil accret corpor op margin
vs management expect contribut
hpc model y/i
model updat revenue vs prior reflect
org cc growth selling-day adjust growth
prior forecast reflect cv steril headwind
revenue vs prior reflect org cc
growth vs prior ep unchang
ep increas vs prior reflect hpc
accret assum get midpoint lrp op
outperform rate pt light neotract acquisit see
clearer pathway toward hsd org sale growth rang
vascular solut vsi close feb neotract close deal organ
mix strong record execut come integr includ
under-promis over-deliv initi synergy/sal target less near-
term cost synergi potenti associ neotract top-lin accret potenti
excit us deal believ potenti transform hsd revenu
grower out-year also think could addit sales/ep momentum
out-year factor model consid increas contribut neotract
ou market bulk exist urolog footprint current sit urolift today
minim presenc eventu revenue contribut ezplaz frozen plasma
project possibl commerci time-frame increas revenue contribut
manta acquir essenti medic acquisit pma approv
potenti futur tuck-in addit restructur opportun addit
program alreadi underway project earn power ep compound-annual-growth-rate
op margin expans potenti given confid top-lin
acceler territori mid-teen ep growth profil -- -both
upper-end peersw think sustain current premium
group assum multipl ep suggest pt
trade ep slightli peer group hospit suppli
compani compani relev
alc trade
ep given confid top-lin acceler hsd territori margin expans
driven acceler mid-to-high teen profit growth profil -- -both upper-
end peersw think sustain premium group appli
multipl turn higher group/ forward multipl ep
suggest pt wed note compani med-tech msd-hsd top line
valuat could risk new product launch organiz improv effort
planned/prior integr synergi cost-cut effort prove challeng take longer
expect implement neotract acquisit integr time fashion
reason uptak compani urolift platform materi quickli
project could put pro forma sales/ep forecast risk well tough competit
larger hospit suppli compani could hinder abil make inroad new
product launch hospitalsin effort rein cost preserv profit given numer
global macroeconom challeng uncertainti relat political/healthcar reform tighten
belt grow less will negoti price hospit suppli product could make
harder drive higher product compani typic sold
discount market rate attempt bring market rate newli launch
achiev sustain price increas key driver long-term gross/oper margin
improv instrument order achiev long-term sales/profit goal
discret item neg impact organ cc revenue growth compani base busi
prove transient take longer resolv expect would like damag
management credibl decreas investor confid org revenue growth acceler thesi
key part invest thesi
dollar million except ep
svb leerink llc estim factset compani inform
dollar million except ep
svb leerink llc estim compani inform
dollar million except ep
compani report svb leerink llc estim
contribut hpc acquisit
headwind steril impact
headwind coronaviru full year
china busi assum return normal busi
april
least y/i growth urolift
market penetr manta midpoint
sell day addit day less day
two addit day
fx expect greatest impact
modest accret hpc acquisit
impact higher share count
lower int expens
expect impact due
dollar million except per share data
good sold
oper incom ex-item amort
pre-tax incom ex-item amort
dilut averag share million
sg adjust sale
sg adjust ex-amort sale
 total sale
oper expens adjust sale
oper expens adjust ex-amort sale
day adj sale organ growth rate ex- acq
compani report svb leerink llc estim
teleflex incorpor restat segment revenu
dollar million except per share data
sale mix
compani report svb leerink llc estim
restat report statement effect januari includ revenu geographi revenu product comparison prior estim
